In the treatment of NAFLD, PPAR overexpression is a general property of steatotic livers, but it seems more likely to affect liver lipid deposition by regulating PPAR and then acting on SREBP. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.